|
HPV | Shim Clinic, Singapore | HIV STD TESTING TREATMENT™
Summary
HPV | Shim Clinic, Singapore | HIV STD TESTING TREATMENT™: Human papillomavirus (HPV) symptoms in men/women, screening/diagnosis, testing/check, treatment clinic, Singapore. Private and confidential service. Definitions, references, and latest news.
Description
Table of Contents HPV / human papillomavirus. There are nearly 200 known types of HPV. They cause Major HPV types: References Genital HPV types, cancer risk, vaccine and test coverage | HPV | 1 6 | 1 8 | 3 1 | 3 3 | 3 5 | 3 9 | 4 5 | 5 1 | 5 2 | 5 6 | 5 8 | 5 9 | 6 8 | 7 0 | 7 3 | 8 2 | 2 6 | 5 3 | 6 6 | 6 | 1 1 | 4 0 | 4 2 | 4 3 | 4 4 | 5 4 | 5 5 | 6 1 | 6 2 | 6 4 | 6 7 | 6 9 | 7 1 | 7 2 | 8 1 | 8 3 | 8 4 | C P 6 1 0 8 | I S 0 3 9 | 7 4 | | Risk | H | H | H | H | H | H | H | H | H | H | H | H | H | H | H | H | I | I | I | L | L | L | L | L | L | L | L | L | L | L | L | L | L | L | L | L | L | L | L | U | | Cervarix | + | + | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | | Gardasil | + | + | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | + | + | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | | V503 | + | + | + | + | - | - | + | - | + | - | + | - | - | - | - | - | - | - | - | + | + | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | | DigeneHR | + | + | + | + | + | + | + | + | + | + | + | + | + | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | | DigenePS | + | + | - | - | - | - | + | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | | CobasHPV | + | + | + | + | + | + | + | + | + | + | + | + | + | - | - | - | - | - | + | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | | Digene | + | + | + | + | + | + | + | + | + | + | + | + | + | - | - | - | - | - | - | + | + | - | + | + | + | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | | HybriBio | + | + | + | + | + | + | + | + | + | + | + | + | + | - | - | - | - | + | + | + | + | - | + | + | + | - | - | - | - | - | - | - | - | - | + | - | - | - | - | - | | PapilloCheck | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | - | + | + | + | + | + | + | + | + | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | | InnoLiPA | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | - | + | + | + | - | - | - | - | - | + | + | - | - | - | - | - | - | + | | LinearArray | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | - | - | + | + | + | + | + | + | + | + | + | + | + | + | + | + | - | Legend: 71 (CP 8061), 81 (CP 8304), 82/MM4, 82/IS039, 83 (MM7), 84 (MM8) References Genital warts: penile warts / vaginal warts / anal warts / anogenital warts / venereal warts / condyloma / condylomata acuminata / "cauliflower" sex disease. References Genital warts appear within 3 months after sexual contact with an infected person. Genital warts: - are usually soft, pink cauliflower-like growths or flesh-coloured bumps on the sex organs
- may also be hard and smooth
- occur alone or in groups
- tend to recur after treatment
- increase the risk of cervical cancer in women.
An infected woman may infect her newborn during childbirth. A person with genital warts can infect others through sexual contact. Genital warts treatment / HPV treatment Cervical cancer HPV vaccine (previously known as cervical cancer vaccine) types: - Gardasil® [HPV (Human Papillomavirus) Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant]
- Cervarix® [HPV (Human Papillomavirus) Bivalent (Types 16 and 18) Vaccine, Recombinant]
- V503 [HPV (Human Papillomavirus) Nonavalent (Types 6, 11, 16, 18, 31, 33, 45, 52, and 58) Vaccine, Recombinant]
References Gardasil® [HPV (Human Papillomavirus) Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant] References Cervarix® [HPV (Human Papillomavirus) Bivalent (Types 16 and 18) Vaccine, Recombinant] References V503 [HPV (Human Papillomavirus) Nonavalent (Types 6, 11, 16, 18, 31, 33, 45, 52, and 58) Vaccine, Recombinant] - to be released in 2013 STD vaccine / hepatitis vaccine shot/jab/injection to prevent some STDs | Vaccine | Against | Disease | Age | D o s e s | Dose schedule | Price per dose (SG$) | | Havrix™ 1440 Adult | Hepatitis A virus | Hepatitis A | ≥19y | 2 | m 0 & 6-12 | $90/= | | Twinrix® | Hepatitis A virus Hepatitis B virus | Hepatitis A Hepatitis B | 1-15y | 2 | m 0, 6-12 | $120/= | | ≥16y | 3 | m 0, 1, 6 | | 4 | d 0, 7, 21 & m 12 | | Inactivated / Fractional / Protein / Subunit / Recombinant | | Engerix™-B 20 μg | Hepatitis B virus | Hepatitis B | 11-15y | 2 | m 0, & 6 | $50/= | | ≥20y | 3 | m 0, 1, & 6 | | 4 | m 0, 1, 2, & 12 or d 0, 7, 21 & m 12 | | Gardasil® | HPV types 6, 11, 16, & 18 | Genital warts Cervical cancer | 9-26y | 3 | m 0, 2, & 6 or m 0, 1, & 4 | $195/= | | Cervarix® | HPV types 16, & 18 (31, 33, & 45) | 10-25y | 3 | m 0, 1, & 6 m 0, 1, & 5 m 0, 2½, 12 | $195/= | | V503 | HPV types 6, 11, 16, 18, 31, 33, 45, 52, & 58 | | 3 | m 0, 2, & 6 or m 0, 1, & 4 | $???/= | HPV test for men/women. - Digene® High-Risk HPV DNA Test
- QIAGEN - digene HC2 High-Risk HPV DNA Test - For detection of human papillomavirus infections using Hybrid Capture 2 technology
- Detects 13 high-risk HPV types: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68.
- Unable to differentiate which types are positive.
- Cost is SG$200/=
- Digene® HPV DNA Test
- QIAGEN - digene HC2 HPV DNA Test - For detection of human papillomavirus infections
- Detects 13 high-risk HPV types: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68. And 5 low-risk types: 6, 11, 42, 43, and 44.
- Unable to differentiate which types are positive.
- Not available in Singapore. Unlikely to be available in the future.
- Digene® HPV Genotyping PS Test
- Hybribio®
- HPV GenoArray Test Kit
- Detects 15 high-risk HPV types: 16, 18, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, and 68. And 6 low-risk HPV types: 6, 11, 42, 43, 44, CP8304
- Able to differentiate which types are positive.
- May be available in Singapore soon.
- Cobas® HPV Test
- Cobas® HPV Test
- Detects 14 high-risk HPV types: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68
- The test specifically identifies (types) HPV 16 and HPV 18, while concurrently detecting the rest of the high risk types (31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68)
- Cost is SG$200/=
- LINEAR ARRAY® HPV Genotyping Test
- LINEAR ARRAY® HPV Genotyping Test
- Identifies 37 high-risk HPV genotypes 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68, 73 (MM9), 82 (MM4) low-risk HPV genotypes 6, 11, 26, 40, 42, 53, 54, 55, 61, 62, 64, 67, 69, 70, 71, 72, 81, 83 (MM7), 84 (MM8), IS39, and CP6108
- INNO-LiPA HPV Genotyping Extra
- INNO-LiPA HPV Genotyping Extra
- Identifies 15 high-risk HPV genotypes (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, 82) 3 probable high-risk HPV genotypes (26, 53, 66) 7 low-risk HPV genotypes (6, 11, 40, 43, 44, 54, 70) and some additional types (69, 71, 74).
- PapilloCheck®
- PapilloCheck®
- Identifies 24 hiv-risk HPV types 16 18 31 33 35 39 45 51 52 53 56 58 59 66 68 70 73 82 and low-risk HPV types 6 11 40 42 43 44
Sexual risk
(of HIV/STD/pregnancy), and what you can do before and after exposure.
Note: If the clinic attendance is only for the HIV rapid test, then consultation fees are not added.
References
Latest News
A review of dietary prevention of human papillomavirus-related infection of the cervix and cervical intraepithelial neoplasia. Fri, 24 May 2013 15:40:03 +0100 | Nutrition and Cancer This study reviews the preventive role of dietary intake on cervical intraepithelial neoplasia (CIN) induced by human papillomavirus (HPV). Electronic databases were searched using relevant keywords such as, but not limited to, human papillomavirus infection, cervical intraepithelial neoplasia, lifestyle factors, nutrients intake, and diet. High consumption of fruit and vegetables appears to be protective against CIN. The findings also highlight the possibility of consuming high levels of specific nutrients, vitamins, and minerals, and retaining sufficient level of these elements in the body, especially those with high antioxidants and antiviral properties, to prevent progression of transient and persistent HPV infections to high-grade CIN 2 and 3 (including in situ cervical cancer). The p... Difference in overall and age-specific prevalence of high-risk human papillomavirus infection in Italy: evidence from NTCC trial Fri, 24 May 2013 04:00:00 +0100 | BMC Infectious Diseases Conclusions: Screening for cervical cancer: a systematic review and meta-analysis Fri, 24 May 2013 04:00:00 +0100 | BioMed Central Conclusions: Comparative evaluation of the Abbott HIV-1 RealTime™ assay with the Standard Roche COBAS(®) Amplicor™ HIV-1 Monitor(®) Test, v1.5 for determining HIV-1 RNA levels in plasma specimens from Pune, India. Thu, 23 May 2013 16:50:03 +0100 | Journal of Virological Methods Authors: Khopkar P, Mallav V, Chidrawar S, Kulkarni S Murine gammaherpesvirus 68 ORF75c contains ubiquitin E3 ligase activity and requires PML SUMOylation but not other known cellular PML regulators, CK2 and E6AP, to mediate PML degradation. Thu, 23 May 2013 13:25:06 +0100 | Virology Authors: Sewatanon J, Ling PD Metagenomic sequencing of "HPV-negative" condylomas detects novel putative HPV types. Thu, 23 May 2013 13:25:06 +0100 | Virology Metagenomic sequencing of "HPV-negative" condylomas detects novel putative HPV types. Does exposure to laser plume place the surgeon at high risk for acquiring clinical human papillomavirus infection? Wed, 22 May 2013 04:00:00 +0100 | The Laryngoscope (Source: The Laryngoscope) Depletion of polycistronic transcripts using short interfering RNAs: cDNA synthesis method affects levels of non-targeted genes determined by quantitative PCR Tue, 21 May 2013 04:00:00 +0100 | Virology Journal Conclusions: High intratumor genetic heterogeneity is related to worse outcome in patients with head and neck squamous cell carcinoma Mon, 20 May 2013 04:00:00 +0100 | Cancer CONCLUSIONSThis novel measure of tumor genetic heterogeneity is significantly associated with tumor progression and adverse treatment outcomes, thereby supporting the hypothesis that higher genetic heterogeneity portends a worse clinical outcome in patients with HNSCC. The prognostic value of some known biomarkers may be the result of their association with high genetic heterogeneity. MATH provides a useful measure of that heterogeneity to be prospectively validated as NGS data from homogeneously treated patient cohorts become available Cancer 2013. © 2013 American Cancer Society. (Source: Cancer) Study Explores Providers' Perceptions Of Parental Concerns About HPV Vaccination Fri, 17 May 2013 07:00:00 +0100 | Health News from Medical News Today A new Boston University School of Medicine (BUSM) study has found that low-income and minority parents may be more receptive to vaccinating their daughters against Human Papillomavirus (HPV), while white, middle-class parents are more likely to defer the vaccination. The findings appear online in the May issue of the Journal of Health Care for the Poor and Underserved. Cervical cancer incidence and mortality are markedly higher for low-income and minority women due to higher rates of HPV and limited access to screening and treatment... (Source: Health News from Medical News Today)
|